Antibe Therapeutics recently introduced PentOS OI Max Bone Graft Substitute, the newest member of the company’s product line of bone grafts for oral and maxillofacial surgery.
The inductive collagen matrix can be mixed with the dentist’s choice of patient derived concentrates, including stem cells and blood components, according to a press release. Osteoinductivity was demonstrated in each lot in both in vivo and in vitro assays using independent labs.
In vitro testing demonstrated levels of bone morphogenetic protein (“BMP”) up to 40 times that of the control, while in vivo testing demonstrated all five elements of bone formation are present in PentOS OI grafts, which are chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone. In vitro studies also demonstrated optimal cell viability and proliferation.
PentOS OI Max will be offered in the Canadian market through the company’s direct sales force and globally via its network of distribution partners.
View Full Press Release
Source: Antibe Therapeutics